Amneal Pharmaceuticals/$AMRX
Amneal shares rise after the FDA approved and the company immediately launched its lanreotide injection, which received Competitive Generic Therapy designation and targets a reference product with nearly $1bn in annual US sales.
3 hours agoLightyear AI
1D1W1MYTD1Y5YMAX
Capital at risk
About Amneal Pharmaceuticals
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
- Ticker
- $AMRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 8,700
- Headquarters
- Bridgewater, United States
- Website
- www.amneal.com
AMRX Metrics
BasicAdvanced
$6.5B
38.91
$0.48
1.25
-
Price and volume
Market cap
$6.5B
Beta
1.25
52-week high
$19.26
52-week low
$9.49
Average daily volume
2M
Financial strength
Current ratio
2.205
Quick ratio
1.3
Long term debt to equity
22.827
Total debt to equity
23.865
Interest coverage (TTM)
2.20%
Profitability
EBITDA (TTM)
689.437
Gross margin (TTM)
39.81%
Net profit margin (TTM)
5.05%
Operating margin (TTM)
15.88%
Effective tax rate (TTM)
-7.03%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
8.60%
Return on equity (TTM)
613.02%
Valuation
Price to earnings (TTM)
38.912
Price to revenue (TTM)
1.896
Price to book
180.85
Price to tangible book (TTM)
-5.2
Price to free cash flow (TTM)
-480.372
Free cash flow yield (TTM)
-0.21%
Free cash flow per share (TTM)
-0.039
Growth
Revenue change (TTM)
9.28%
Earnings per share change (TTM)
4,332.00%
3-year revenue growth (CAGR)
10.48%
3-year earnings per share growth (CAGR)
229.37%
What the Analysts think about AMRX
Analyst ratings (Buy, Hold, Sell) for Amneal Pharmaceuticals stock.
Analyst projections of the future price of Amneal Pharmaceuticals stock.
Bulls say / Bears say
Amneal’s second-quarter revenue rose 10% to $796 million, with Specialty up 17% and Affordable Medicines up 13%. It raised 2026 revenue guidance to $3.10-$3.20 billion and adjusted EBITDA guidance to $750-$780 million, showing that growth is broadening beyond one product. (GlobeNewswire)
The FDA approved and Amneal immediately launched its lanreotide injection, a complex oncology product with Competitive Generic Therapy designation. The launch adds a sizeable new opportunity to Affordable Medicines and uses Amneal’s in-house sterile manufacturing capacity. (Amneal Pharmaceuticals)
The Kashiv BioSciences transaction could give Amneal an integrated biosimilars platform spanning development, manufacturing, regulatory work and commercial supply. That would diversify the company away from lower-value generics and position it for a large wave of biologic patent expiries over the next decade. (Amneal Pharmaceuticals)
Amneal had $2.68 billion of total debt at the end of June and incurred $108.4 million of net interest expense in the first half. Operating cash flow was negative $48.0 million, leaving less room for debt reduction, acquisitions or unexpected setbacks. (Last10K)
Rytary has lost exclusivity, with an authorised generic already available and further generic entrants expected. That could erode Specialty revenue, while intense generic competition may pressure prices and margins even if volumes grow. (Yahoo Finance)
The growth plan is demanding operationally: Amneal raised 2026 capital expenditure guidance from about $110 million to $150 million and expects a roughly $20 million hit from flooding at an India facility. Capacity expansion and disruption could weigh on cash generation before new products deliver their expected returns. (The Motley Fool, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2026.
AMRX Financial Performance
Revenues and expenses
AMRX Earnings Performance
Company profitability
Upcoming events
No upcoming events
AMRX News
AllArticlesVideos
Funds containing AMRX
AllUSDGBPEUR
Fund name | Fund size | $AMRX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.39% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.39% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.18% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.18% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.